• Carlos J Montoya, Edwin A Higuita, Santiago Estrada, Francisco J Gutierrez, Pedro Amariles, Newar A Giraldo, Margarita M Jimenez, Claudia P Velasquez, Alba L Leon, Maria T Rugeles, and Fabian A Jaimes.
• Immunovirology Group, University of Antioquia, Calle 62, 52 - 59, Medellin, Colombia. cjmonto@gmail.com
• J. Infect. 2012 Dec 1; 65 (6): 549-58.

BackgroundEvidence suggests that statins may modify the immune response against HIV. The aim was to evaluate the antiretroviral and immunomodulatory effects of lovastatin in HIV-infected patients, naïve for antiretroviral therapy.MethodsRandomized, double-blinded, placebo-controlled, phase-II clinical trial. Primary outcomes were plasma viral load and circulating CD4+ T cell count, after 6 and 12 months of treatment; secondary outcomes were CD8+ T cell count, expression of activation markers (CD38 and HLA-DR) on T cells, and clinical outcomes. With a power of 90% to detect both a decrease of 0.3 log10 in plasma HIV-1 RNA copies and an increase of 20% in the CD4+ T cell count, we estimated a required sample size of 110 HIV-infected patients (55 per group). The results were analyzed by a model of repeated measurements using Generalized Estimating Equations.ResultsPatients were randomized to receive either lovastatin (n = 55) or placebo (n = 57). During the 12-month follow-up, there was no effect of lovastatin either on viral load (estimated average change = 0.157 copies/mL; CI 95% = -0.099 to 0.414), or on the CD4+ T cell count (estimated average change = -26.1 cells/μL; CI 95% = -89.8 to 37.6). Moreover, there were no significant differences in secondary outcomes.ConclusionsDaily administration of lovastatin (40 mg) for one year in HIV-infected patients, naïve for antiretroviral therapy, had no significant effect on HIV replication, the CD4+ T cell count, or the activation level of T cells. (www.clinicaltrials.gov; ID NCT00721305).Copyright © 2012 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

29 keywords...

hide…